Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-fluorouracil + folinic acid + gemcitabine + oxaliplatin
- Development stage
- Phase 2
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This is a four-drug chemotherapy combination consisting of 5-fluorouracil (5-FU), folinic acid (leucovorin), gemcitabine, and oxaliplatin. Each component has a distinct mechanism of action: - **5-fluorouracil** is an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis. - **Folinic acid** enhances the binding of 5-FU to thymidylate synthase, increasing its cytotoxicity. - **Gemcitabine** is a nucleoside analog that incorporates into DNA and inhibits DNA synthesis by blocking ribonucleotide reductase. - **Oxaliplatin** is a platinum-based agent that forms crosslinks in DNA, leading to apoptosis. This combination has been investigated primarily for advanced or metastatic gastrointestinal cancers such as gastric cancer and esophageal cancer. The regimen aims to leverage synergistic effects between these agents for improved anti-tumor activity[1][3]. It remains investigational and has been studied in phase II clinical trials.
- Other names
- GEM+FOLFOX-4gemcitabine plus FOLFOXgemcitabine/oxaliplatin/5-fluorouracil/folinic acid
02
Targets
DNADNA polymerase familyRNR (Ribonucleotide reductase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on 5-fluorouracil + folinic acid + gemcitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5-fluorouracil + folinic acid + gemcitabine + oxaliplatin.